|1.||Friedman, Lori S: 10 articles (03/2014 - 09/2008)|
|2.||Belvin, Marcia: 9 articles (03/2014 - 06/2009)|
|3.||Salphati, Laurent: 6 articles (07/2014 - 09/2008)|
|4.||Sampath, Deepak: 6 articles (03/2014 - 05/2009)|
|5.||Wallin, Jeffrey J: 5 articles (03/2014 - 07/2010)|
|6.||Berry, Leanne: 4 articles (01/2013 - 07/2010)|
|7.||Prior, Wei Wei: 4 articles (07/2012 - 07/2010)|
|8.||Fulda, Simone: 3 articles (02/2015 - 01/2012)|
|9.||Pang, Jodie: 3 articles (07/2014 - 09/2008)|
|10.||Edgar, Kyle A: 3 articles (03/2014 - 09/2010)|
05/01/2013 - "Tumor uptake of [(18)F]-FLT was significantly reduced following GDC-0941 dosing in responsive tumors at the acute time point and correlated with pharmacodynamic markers of PI3K signaling inhibition and significant reduction in TK1 expression in U87, but not HCT116, tumors. "
01/17/2013 - "Further, we used this model to test the efficacy of GDC-0941, a PI3K inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition."
10/24/2014 - "Recently, a new generation of PI3K-specific inhibitors, such as GDC0941 and BKM120, are being investigated in clinical trials for treatment against tumors harboring PIK3CA mutations. "
09/25/2008 - "This work resulted in the discovery of 17, GDC-0941, which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clinical trials for the treatment of cancer."
05/10/2015 - "GDC-0941 exhibited minimal tumor inhibition in MDA-MB-231 cells, but it significantly suppressed tumor growth in HER-positive SK-BR3 cells. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/2014 - "More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro."
01/01/2014 - "The proliferation of breast cancer cells was measured by MTT assay in the presence of GDC-0941. "
10/15/2011 - "Additional combinations of T-DM1 (for example, with GDC-0941) and additional disease settings (early-stage HER2-positive breast cancer) are also under investigation. "
06/15/2009 - "The addition of GDC-0941 to HER2-directed treatment could augment clinical benefit in breast cancer patients."
06/15/2009 - "GDC-0941 is efficacious in preclinical models of breast cancer. "
01/01/2012 - "Treatment with GDC-0941 led to approximately three-fold increases in perfusion, substantially reduced hypoxia and vascular normalization by histology. "
12/01/2011 - "GDC-0941 reduced spreading and migration in all O(2) conditions, whereas dnHIF had an impact only on hypoxia-induced migration (P < 0.001). "
12/01/2011 - "GDC-0941 inhibited hypoxia/anoxia-induced HIF-1α and HIF-2α expression and HIF activity in thyroid carcinoma cells. "
02/01/2013 - "Combined treatment with selective class I PI3K inhibitor GDC-0941 and sorafenib reversed the protective effects of bone marrow stromal cells on FLT3-mutant AML cells in hypoxia, which was associated with downregulation of Pim-1 and Mcl-1 expression levels. "
12/01/2013 - "Here, we demonstrate the antileukemic effects of simultaneous inhibition of PI3K by the selective class I PI3K inhibitor GDC-0941 and of Bcl-2 family members by the BH3 mimetic ABT-737 in the context of the bone marrow microenvironment, where hypoxia and interactions with bone marrow stromal cells promote AML cell survival and chemoresistance. "
|4.||Glioblastoma (Glioblastoma Multiforme)
02/01/2013 - "By identifying the combination of GDC-0941 and B10 as a new, potent strategy to trigger cell death in glioblastoma cells, our findings have important implications for the development of novel treatment approaches for glioblastoma."
02/01/2013 - "Importantly, parallel experiments in primary glioblastoma cultures similarly show that GDC-0941 and B10 cooperate to trigger cell death, underscoring the clinical relevance of this finding. "
02/01/2013 - "GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death."
07/01/2014 - "ABT-263 (Navitoclax), an orally available small-molecule Bcl-2 inhibitor, and GDC-0941, a PI3K inhibitor, were used to treat established glioblastoma and glioblastoma neurosphere cells, alone or in combination. "
02/01/2013 - "Here, we discover that the PI3K inhibitor GDC-0941 acts in concert with the natural compound B10, a glycosylated derivative of betulinic acid, to induce cell death in glioblastoma cells. "
05/01/2013 - "CBA nude mice bearing U87 glioma and HCT116 colorectal xenografts were imaged at baseline with [(18)F]-FLT and at acute (18 hours) and chronic (186 hours) time points after twice-daily administration of GDC-0941 (50 mg/kg) or vehicle. "
06/01/2011 - "The efficacy of MG18L in human GSCs and glioma cell lines in vitro was compared with other oHSVs, alone or in combination with phosphoinositide-3-kinase (PI3K)/Akt inhibitors (LY294002, triciribine, GDC-0941, and BEZ235). "
|4.||DNA (Deoxyribonucleic Acid)
|5.||sorafenib (BAY 43-9006)
|7.||2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- one
|9.||Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
|1.||Heterologous Transplantation (Xenotransplantation)